DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is partnering with MediOrbis, a telehealth provider specializing in chronic conditions, to provide remote patient monitoring services to Medicare patients with diabetes. The new virtual care initiative means that Medicare patients who have diabetes and who are eligible can receive convenient virtual care that is covered under their existing Medicare benefits. The telehealth services are delivered by MediOrbis with remote patient monitoring through DarioHealth’s AI-powered digital chronic care platform. The announcement noted that the new virtual care program will be available to Dario’s approximately 75,000 members with diabetes. Because an estimated 30% of those members are over age 65, the benefit to these members could be significant, enabling them to benefit from this high-quality, convenient care at lower out-of-pocket costs. The program will also be offered to qualified Medicare members who aren’t using Dario’s offering. “We are excited to partner with MediOrbis to launch this virtual care service for qualified Medicare beneficiaries,” said DarioHealth president and North America general manager Rick Anderson in the press release. “Offering our existing users this program provides users with enhanced services and support at a lower cost. Increasing our offerings to existing customers across all of our market segments is part of our strategy to improve value to our users while increasing revenue per member and lowering our average member acquisition cost. We are excited to partner with MediOrbis and support the expansion beyond Dario’s existing user base to the broader Medicare population, which we believe has the potential to be a multimillion dollar remote patient monitoring opportunity for Dario.”
To view the full press release, visit https://ibn.fm/ZQTKp
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php